Dr. Hassan M. Alnuaimat

Intensive Care Medicine
Uf Health Medical Specialties-Medical Plaza
1549 Gale Lemerand Dr, 
Gainesville, FL 
Accepting New Patients
Referral may be required
Before you request
Uf Health Medical Specialties-Medical Plaza
1549 Gale Lemerand Dr, 
Gainesville, FL 

Overview

Hassan Alnuaimat is an Intensive Care Medicine provider practicing medicine in Gainesville, Florida.

His clinical expertise encompasses Arteriovenous Malformation and Endoscopy.

He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 11 clinical trials. Dr. Alnuaimat is currently accepting new patients.

Specialties

Intensive Care Medicine

Licenses

Anesthesiology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Uf Health Medical Specialties-Medical Plaza
1549 Gale Lemerand Dr, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

42 Total Publications

Serpiginous-Like Choroiditis with ANCA-PR3 Vasculitis in a Patient from Endemic Country: A Complex Phenotypic, Immunological and Epidemiological Puzzle.
Serpiginous-Like Choroiditis with ANCA-PR3 Vasculitis in a Patient from Endemic Country: A Complex Phenotypic, Immunological and Epidemiological Puzzle.
Journal: Ocular immunology and inflammation
Published: December 10, 2024
Similar Doctors
Expertise in
5
conditions
Dr. Hiren J. Mehta
Intensive Care Medicine
Expertise in
5
conditions
Dr. Hiren J. Mehta
Intensive Care Medicine
Referral may be required
Before you request

Uf Health Medical Specialties-Medical Plaza

1549 Gale Lemerand Dr, 
Gainesville, FL 
 (0.1 miles away)
352-273-8740
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hiren Mehta is an Intensive Care Medicine provider practicing medicine in Gainesville, Florida. Dr. Mehta is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Lung Nodules, ALK-Positive Non-Small Cell Lung Cancer, Emphysema, Endoscopy, and Gastrostomy. Dr. Mehta is currently accepting new patients.

Expertise in
27
conditions
Dr. Andrew R. Seevaratnam
Intensive Care Medicine | Pulmonary Medicine
Expertise in
27
conditions
Dr. Andrew R. Seevaratnam
Intensive Care Medicine | Pulmonary Medicine
Referral may be required
Before you request

Ocala Lung & Critical Care Associates, Inc.

10969 SE 175th Pl Ste 200, 
Summerfield, FL 
 (47.8 miles away)
352-732-5552
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Seevaratnam is an Intensive Care Medicine specialist and a Pulmonary Medicine provider practicing medicine in Summerfield, Florida. Dr. Seevaratnam is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Hospital-Acquired Pneumonia, Advanced Bronchoscopy, and Gastrostomy. Dr. Seevaratnam is board certified in American Board Of Internal Medicine. Dr. Seevaratnam is currently accepting new patients.

Expertise in
4
conditions
Dr. Michael A. Jantz
Intensive Care Medicine
Expertise in
4
conditions
Dr. Michael A. Jantz
Intensive Care Medicine
Referral may be required

North Florida Surgical Associates LLC

1121 NW 64th Ter Ste A, 
Gainesville, FL 
 (3.2 miles away)
352-331-5026
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Jantz is an Intensive Care Medicine provider practicing medicine in Gainesville, Florida. Dr. Jantz is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Nodules, Emphysema, ALK-Positive Non-Small Cell Lung Cancer, Endoscopy, and Gastrostomy. Dr. Jantz is currently accepting new patients.

Frequently Asked Questions about Dr. Hassan M. Alnuaimat

How do I make an appointment with Dr. Hassan M. Alnuaimat?

You can book an appointment with Dr. Hassan M. Alnuaimat by calling their office at 352-265-8940. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hassan M. Alnuaimat a top-rated expert for Arteriovenous Malformation?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hassan M. Alnuaimat is classified as an Experienced expert for Arteriovenous Malformation, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hassan M. Alnuaimat specialize in?

While Dr. Hassan M. Alnuaimat is a Intensive Care Medicine, they have specific expertise in Arteriovenous Malformation, Endoscopy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Hassan M. Alnuaimat participate in research or clinical trials?

Yes. Dr. Hassan M. Alnuaimat has published 42 articles and abstracts on conditions like Arteriovenous Malformation. You can view a list of Dr. Hassan M. Alnuaimat's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hassan M. Alnuaimat accept my insurance?

Dr. Hassan M. Alnuaimat accepts most major insurance plans, including Humana. We recommend calling the office directly at 352-265-8940 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alnuaimat's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile